CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AB6. A total of 12 filers reported holding CLOVIS ONCOLOGY INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $7,000 | +75.0% | 94,254 | +9.5% | 0.00% | – |
| Q4 2020 | $4,000 | 0.0% | 86,044 | +26.0% | 0.00% | – |
| Q3 2020 | $4,000 | -20.0% | 68,266 | -0.0% | 0.00% | – |
| Q2 2020 | $5,000 | +66.7% | 68,267 | +44.5% | 0.00% | – |
| Q1 2020 | $3,000 | -99.3% | 47,257 | -98.8% | 0.00% | -100.0% |
| Q4 2019 | $416,000 | +110.1% | 3,974,000 | -18.0% | 0.00% | +100.0% |
| Q3 2019 | $198,000 | – | 4,844,000 | +29.7% | 0.00% | – |
| Q2 2019 | $0 | – | 3,734,000 | -46.2% | 0.00% | – |
| Q1 2019 | $0 | – | 6,938,000 | -46.3% | 0.00% | – |
| Q4 2018 | $0 | – | 12,909,000 | +82.6% | 0.00% | – |
| Q3 2018 | $0 | – | 7,071,000 | +279.3% | 0.00% | – |
| Q2 2018 | $0 | – | 1,864,000 | -88.4% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 16,028,000 | +701.4% | 0.00% | -100.0% |
| Q2 2017 | $3,385,000 | +609.6% | 2,000,000 | +599.3% | 0.01% | +300.0% |
| Q3 2015 | $477,000 | – | 286,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| QVT Financial LP | 43,295,000 | $29,665,000 | 1.82% |
| Telemetry Investments, L.L.C. | 7,000,000 | $4,747,000 | 1.38% |
| Baker Brothers Advisors | 129,300,000 | $87,801,000 | 0.93% |
| Castle Creek Arbitrage, LLC | 5,500,000 | $3,755,000 | 0.30% |
| WOLVERINE ASSET MANAGEMENT LLC | 14,300,000 | $9,730,000 | 0.28% |
| Verition Fund Management LLC | 1,966,000 | $1,343,000 | 0.22% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 11,625,000 | $7,960,000,000 | 0.15% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 6,000,000 | $4,106,000 | 0.12% |
| PFM Health Sciences, LP | 4,747,000 | $3,243,000 | 0.10% |
| ARROWGRASS CAPITAL PARTNERS (US) LP | 11,500 | $3,568,000 | 0.04% |